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https://doi.org/10.1016/j.chembiol.2020.06.013SUMMARYThe affinity-directed protein missile (AdPROM) system utilizes specific polypeptide binders of intracellular
proteins of interest (POIs) conjugated to an E3 ubiquitin ligase moiety to enable targeted proteolysis of the
POI. However, a chemically tuneable AdPROM system ismore desirable. Here, we use Halo-tag/VHL-recruit-
ing proteolysis-targeting chimera (HaloPROTAC) technology to develop a ligand-inducible AdPROM (L-Ad-
PROM) system. When we express an L-AdPROM construct consisting of an anti-GFP nanobody conjugated
to the Halo-tag, we achieve robust degradation of GFP-tagged POIs only upon treatment of cells with the Hal-
oPROTAC. For GFP-tagged POIs, ULK1, FAM83D, and SGK3were knocked in with a GFP-tag using CRISPR/
Cas9. By substituting the anti-GFP nanobody for a monobody that binds H- and K-RAS, we achieve robust
degradation of unmodified endogenous RAS proteins only in the presence of the HaloPROTAC. Through sub-
stitution of the polypeptide binder, the highly versatile L-AdPROM system is useful for the inducible degra-
dation of potentially any intracellular POI.INTRODUCTION
Developments in RNA interference (RNAi) and CRISPR/Cas9
technologies have enabled the manipulation of specific proteins
of interest (POIs) to study and understand their biological func-
tions (Elbashir et al., 2001; Cong et al., 2013; Doudna and Char-
pentier, 2014; Sander and Joung, 2014). However, as RNAi indi-
rectly depletes target protein expression through the disruption
of messenger RNA, and therefore is reliant on natural protein
turnover, it can be inefficient and time-consuming, especially
when targeting proteins with slow turnover rates (Elbashir
et al., 2001; Jansen et al., 2007; Smoak et al., 2016). In addition,
RNAi has been shown to introduce off-target effects (Rossi et al.,
2015). The generation of target protein knockout (KO) cell lines
using CRISPR/Cas9 genome editing technology can be time
consuming and is not feasible for every target protein, particu-
larly when targeting genes that are essential for cell survival or
proliferation (Wang et al., 2015), or for every cell line. Therefore,
advances in targeted protein degradation technologies could
overcome these current limitations.Cell Chemical Biology 27, 1–17, A
This is an open access article under the CC BY-NThe ubiquitin-proteasome system (UPS) plays a fundamental
role in the degradation of proteins to maintain cellular homeosta-
sis (Roos-Mattjus and Sistonen, 2004; Pines and Lindon, 2005).
Through sequential actions of the E1 ubiquitin-activating
enzyme, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin li-
gases, target proteins are covalently labeled with ubiquitin
chains, marking them for recognition and degradation by the
proteasome (Scheffner et al., 1995). The Cullin (CUL) really inter-
esting new gene (RING) E3 ligase (CRL) family plays a funda-
mental role in regulating protein turnover in cells through the
UPS (Wenzel et al., 2011; Zhao et al., 2012). CRLs are activated
through NEDDylation, where the small ubiquitin-like modifier
NEDD8 (neural precursor cell expressed developmentally down-
regulated protein 8) is covalently attached to a lysine residue of
the CUL (Soucy et al., 2009). CUL2-CRL is in a complex with
Elongin B and C adaptors, the substrate receptor von Hippel-
Lindau (VHL) protein and the RING-box protein 1 (RBX1) E3
ligase (Cardote et al., 2017). Under normoxic conditions, VHL
binds to hydroxy-proline-modified hypoxia-inducible factor 1a
(HIF1a) and brings HIF1a in close proximity to RBX1 for itsugust 20, 2020 ª 2020 The Author(s). Published by Elsevier Ltd. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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(Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001).
Through the exploitation of the endogenous CUL2-CRL ma-
chinery and small polypeptide binders of target proteins, we
recently reported an efficient affinity-directed protein missile
(AdPROM) system for the proteolysis of endogenous target pro-
teins (Fulcher et al., 2016, 2017). AdPROM was engineered with
VHL tethered to, for example, an anti-GFP nanobody (aGFP) for
either constitutive or tetracycline (Tet)-inducible degradation of
GFP-tagged proteins knocked in using CRISPR/Cas9. However,
Tet-inducible AdPROM necessitates the generation of multi-
component cell lines, is often leaky, and relies on transcription
and translation of the AdPROM constructs, thereby limiting rapid
target protein degradation.
To overcome these limitations, a robust tractable AdPROM
system able to achieve rapid and chemically tuneable degrada-
tion of target proteins is desirable. Small-molecule approaches,
including the use of proteolysis-targeting chimeras (PROTACs),
for rapid target protein degradation have been previously re-
ported (Bondeson et al., 2015; Bondeson and Crews, 2017).
PROTACs are heterobifunctional molecules that bring a target
protein into spatial proximity with an E3 ubiquitin ligase to
trigger target ubiquitylation and subsequent proteasomal
degradation (Sakamoto et al., 2001; Lucas and Ciulli, 2017;
Toure and Crews, 2016). PROTACs that hijack CUL2-CRL us-
ing derivatives of the VHL ligand’s hydroxyproline have been
developed to induce degradation of the bromodomain (BRD)
and extra-terminal domain proteins BRD2, BRD3, and BRD4,
and the estrogen-related receptor a (ERRa) in cells and in vivo
(Bondeson et al., 2015; Zengerle et al., 2015; Gadd et al.,
2017). Halo-based PROTACs that simultaneously bind the
Halo-tag (Los et al., 2008; Ohana et al., 2009) and VHL through
distinct binding moieties have previously been described for
the inducible degradation of overexpressed Halo-tagged target
proteins (Buckley et al., 2015; Tomoshige et al., 2016). More
recently, HaloPROTAC-E was developed for the inducible
degradation of target proteins consisting of a Halo-tag knocked
in using CRISPR/Cas9 technology (Tovell et al., 2019a). Howev-
er, highlighting the difficulty of achieving homozygous integra-
tion of a non-fluorescent Halo-tag onto target genes, it was
only possible to isolate a clone where Halo-tag was inserted
on one allele of SGK3 (serum and glucocorticoid-induced pro-
tein kinase 3) (Tovell et al., 2019a), whereas multiple clones for
the homozygous integration of a GFP-tag on SGK3 were
achieved (Malik et al., 2018). By expressing an AdPROM
construct consisting of a target protein-specific polypeptide
binder conjugated to the Halo-tag, we sought to utilize Halo-
PROTAC-E for the inducible degradation of target proteins.Figure 1. GFP-ULK1 and FAM83D-GFP Are Degraded with HaloPROTA
(A) Schematic representation of FLAG-aGFP6M-Halo HaloPROTAC L-AdPROM s
(B and E) ARPE-19 ULK1GFP/GFP (B) and U2OS FAM83DGFP/GFP (E) FLAG-em
immunoprecipitation (IP) with anti-FLAG M2 resin. F.T., post-IP flow-through ext
(C) ARPE-19 ULK1GFP/GFP FLAG-empty and FLAG-aGFP6M-Halo-expressing cel
(D) Quantification of relative GFP-ULK1 protein levels from (C) normalized to load
(F) U2OS FAM83DGFP/GFP FLAG-empty and FLAG-aGFP6M-Halo-expressing cell
(G) Quantification of relative FAM83D-GFP protein levels from (F) normalized to l
Statistical analyses were carried out by one-way analysis of variance using Dunne
resolved by SDS-PAGE and transferred on to PVDF membranes, which were suRESULTS
GFP-ULK1 and FAM83D-GFP Are Degraded with
HaloPROTAC-E in Cells Expressing FLAG-aGFP6M-Halo
First, we developed a ligand-inducible AdPROM (L-AdPROM)
construct, consisting of aGFP conjugated to the Halo-tag and
tagged with a FLAG reporter, for the degradation of GFP-tagged
POIs only in the presence of HaloPROTAC-E (Figure 1A). Rather
than use constructs that yield overexpression of aGFP relative to
the target, an antigen-stabilized aGFP mutant (aGFP6M) was uti-
lized (Tang et al., 2016). In this case, aGFP6M is only stable when
bound to GFP and destabilized and degraded when unbound,
thereby maintaining homeostatic FLAG-aGFP6M-Halo levels
close to a 1:1 ratio to POI-GFP. In the presence of POI-GFP,
FLAG-aGFP6M-Halo binds POI-GFP with high affinity. Treating
these cells with HaloPROTAC-E then recruits FLAG-aGFP6M-
Halo bound to POI-GFP to VHL. Consequently, the POI-
GFP:FLAG-aGFP6M-Halo complex is ubiquitylated by the
CUL2-CRL machinery and degraded by the proteasome.
To analyze the expression of FLAG-aGFP6M-Halo in the
absence or presence of GFP, GFP was transiently expressed
with increasing concentrations of cDNA in both U2OS wild-
type (WT) cells and those transduced with retrovirus encoding
FLAG-aGFP6M-Halo (Figure S1A). As expected, GFP protein
expression in both cell lines increased with increasing concen-
trations of cDNA used for transfection. In cells transduced with
FLAG-aGFP6M-Halo, low levels of FLAG-aGFP6M-Halo protein
expression were detected in untransfected control cells, which
increased with increasing levels of GFP, suggesting that the an-
tigen-dependent nature of aGFP6M ensures that the homeostatic
level of FLAG-aGFP6M-Halo is controlled by POI-GFP protein
abundance. To determine whether unbound FLAG-aGFP6M-
Halo destabilization was facilitated by the proteasome, U2OS
FLAG-aGFP6M-Halo-expressing cells were treated with the pro-
teasome inhibitor MG132 (Figure S1B). In MG132-treated cells,
an increase in poly-ubiquitylated conjugates (Ub) was observed
compared with DMSO-treated controls, suggesting successful
inhibition of the proteasome. Under these conditions, stabiliza-
tion of FLAG-aGFP6M-Halo was observed in MG132-treated
FLAG-aGFP6M-Halo-expressing cells relative to DMSO-treated
controls, suggesting that unbound FLAG-aGFP6M-Halo destabi-
lization is facilitated by the proteasome.
For initial analyses of the FLAG-aGFP6M-Halo L-AdPROM sys-
tem, FLAG-aGFP6M-Halo was expressed by retroviral transduc-
tion in ARPE-19 ULK1 GFP knockin (KI) (ULK1GFP/GFP) cells,
which were generated using CRISPR/Cas9 technology (Fig-
ure S2). ULK1 (unc-51-like kinase 1) is a serine/threonine protein
kinase that plays a key role in the initiation of autophagy, a crucialC-E in Cells Expressing FLAG-aGFP6M-Halo
ystem.
pty and FLAG-aGFP6M-Halo-expressing cells were lysed and subjected to
ract.
ls were treated with 250 nM HaloPROTAC-E for 24 h.
ing control ± SD of n = 14 independent experiments.
s were treated with 1 mM HaloPROTAC-E for 24 h.
oading control ±SD of n = 9 independent experiments.
tt’s post-test; n.s., not significant. For (B), (C), (E), and (F), extracts and IPs were
bjected to immunoblotting with indicated antibodies.
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mechanism to recycle damaged, toxic, or excess cellular com-
ponents and maintain protein synthesis under starvation condi-
tions (Zachari and Ganley, 2017). Anti-FLAG immunoprecipita-
tions (IPs) from ULK1GFP/GFP FLAG-aGFP6M-Halo expressing,
but not FLAG-empty control, cell extracts co-precipitated
GFP-ULK1 (Figure 1B), which was depleted from flow-through
extracts, confirming that FLAG-aGFP6M-Halo interacts with
GFP-ULK1. To assess HaloPROTAC-E-mediated GFP-ULK1
degradation in these cells, both ULK1GFP/GFP FLAG-empty con-
trol and FLAG-aGFP6M-Halo-expressing cells were treated with
increasing concentrations of HaloPROTAC-E (0.05–1 mM) for
24 h (Figure S3A). No change in GFP-ULK1 levels were observed
in HaloPROTAC-E-treated FLAG-empty cells. However, in
FLAG-aGFP6M-Halo-expressing cells, a reduction in GFP-
ULK1 levels was observed with 0.25, 0.5, and 1 mM HaloPRO-
TAC-E. Parallel degradation of FLAG-aGFP6M-Halo was also
observed at these HaloPROTAC-E concentrations, either due
to co-degradation or destabilizing mutations triggering proteoly-
sis once the bound cargo was degraded. To analyze the time-
dependent degradation of GFP-ULK1 with HaloPROTAC-E,
ULK1GFP/GFP FLAG-empty control and FLAG-aGFP6M-Halo-ex-
pressing cells were treated with 250 nM HaloPROTAC-E for 2,
4, 6, and 24 h (Figure S3B). Both GFP-ULK1 and FLAG displayed
time-dependent degradation upon treatment with HaloPRO-
TAC-E only in FLAG-aGFP6M-Halo-expressing cells, with
optimal degradation achieved after 24 h. Following HaloPRO-
TAC-E treatment optimization, ULK1GFP/GFP FLAG-empty con-
trol and FLAG-aGFP6M-Halo-expressing cells were treated with
250 nM HaloPROTAC-E for 24 h and GFP-ULK1 protein levels
were quantified (Figures 1C and 1D). Although a slight but signif-
icant stabilization of GFP-ULK1 was observed upon FLAG-
aGFP6M-Halo expression compared with DMSO-treated FLAG-
empty control cells, a mean 65% reduction in GFP-ULK1 protein
levels was observed with HaloPROTAC-E.
To determine the applicability and versatility of the HaloPRO-
TAC L-AdPROMsystem, FLAG-aGFP6M-Halo was expressed by
retroviral transduction in U2OS FAM83D GFP KI (FAM83DGFP/
GFP) cells (Fulcher et al., 2019), and HaloPROTAC-E-mediated
FAM83D-GFP degradation assessed. FAM83D belongs to the
FAMily with sequence similarity 83 (FAM83) family of poorly
characterized proteins (Bozatzi and Sapkota, 2018; Fulcher
et al., 2018). FAM83D is required for the recruitment of casein ki-
nase 1a (CK1a) to the mitotic spindle to orchestrate proper spin-
dle positioning and timely cell division (Fulcher et al., 2019).
FAM83D-GFP co-precipitated only with anti-FLAG IPs from
FAM83DGFP/GFP FLAG-aGFP6M-Halo-expressing cells (Fig-
ure 1E), and not FLAG-empty control cells, confirming that
FLAG-aGFP6M-Halo interacts with FAM83D-GFP. Treatment of
FAM83DGFP/GFP FLAG-aGFP6M-Halo-expressing cells with
increasing concentrations of HaloPROTAC-E (0.25–2 mM) for
24 h resulted in a decrease in FAM83D-GFP levels in a dose-
dependent manner (Figure S3C), while no degradation was
evident in FLAG-empty control cells. Optimal FAM83D-GFP
degradation was observed with 1 mM HaloPROTAC-E, with sta-
bilization observed at 2 mM. This high-dose hook effect is where
degradation is decreased at high compound concentrations as
the formation of binary complexes outcompetes the active
ternary complexes (Douglass et al., 2013). To analyze4 Cell Chemical Biology 27, 1–17, August 20, 2020FAM83D-GFP degradation kinetics with HaloPROTAC-E,
FAM83DGFP/GFP FLAG-empty, and FLAG-aGFP6M-Halo-ex-
pressing cells were treated with 1 mM HaloPROTAC-E for 2, 4,
6, and 24 h (Figure S3D). In HaloPROTAC-E-treated FLAG-
aGFP6M-Halo-expressing cells, FAM83D-GFP was degraded in
a time-dependent manner, with optimal degradation achieved
after 24 h. FAM83D-GFP levels were then quantified 24 h after
1 mM HaloPROTAC-E treatment (Figures 1F and 1G). Although
a slight but significant stabilization of FAM83D-GFP was
observed upon FLAG-aGFP6M-Halo expression compared with
DMSO-treated FLAG-empty control cells, a mean 65% reduc-
tion in FAM83D-GFP protein levels was observedwith HaloPRO-
TAC-E.
Characterization of HaloPROTAC-E L-AdPROM-
Mediated GFP-ULK1 and FAM83D-GFP Degradation
To determine whether HaloPROTAC-E-mediated degradation of
GFP-ULK1 and FAM83D-GFP in FLAG-aGFP6M-Halo-express-
ing cells requires the binding of HaloPROTAC-E to Halo, an
FLAG-aGFP6M-Halo
D106A mutant that cannot bind the ligand
(Neklesa et al., 2011) was expressed in ARPE-19 ULK1GFP/GFP
(Figure 2A) and U2OS FAM83DGFP/GFP (Figure 2B) cells by retro-
viral transduction. In these cells, HaloPROTAC-E treatment
failed to degrade either GFP-ULK1 (Figure 2A) or FAM83D-
GFP (Figure 2B), suggesting that the HaloPROTAC-E:Halo inter-
action is necessary for GFP-ULK1 and FAM83D-GFP degrada-
tion in FLAG-aGFP6M-Halo-expressing cells. Next, to assess
whether HaloPROTAC-E-mediated degradation of GFP-ULK1
and FAM83D-GFP in FLAG-aGFP6M-Halo-expressing cells re-
quires the binding of HaloPROTAC-E to VHL, a competition
assay with the VHL inhibitor VH298 (Frost et al., 2016), which
the VHL warhead of HaloPROTAC-E is based on, was estab-
lished (Figures 2C and 2D). VH298 not only stabilized HIF1a pro-
tein levels, thereby confirming the inhibition of VHL, but also in-
hibited the degradation of both GFP-ULK1 (Figure 2C) and
FAM83D-GFP (Figure 2D) caused by HaloPROTAC-E in the
respective FLAG-aGFP6M-Halo-expressing cells. These data
suggest that HaloPROTAC-E successfully binds VHL to mediate
GFP-ULK1 and FAM83D-GFP degradation in FLAG-aGFP6M-
Halo-expressing cells. On the other hand, neither HaloPRO-
TAC-E treatment nor FLAG-aGFP6M-Halo expression in cells
influenced HIF1a levels (Figures 2C and 2D), suggesting that
they do not interfere with the endogenous VHL-CUL2-CRL ma-
chinery. To determine whether HaloPROTAC-E-mediated GFP-
ULK1 and FAM83D-GFP degradation was facilitated by the
CUL-CRL machinery, the pan-CUL NEDDylation inhibitor
MLN4924 (Soucy et al., 2009) was utilized (Figures 2E and 2F).
MLN4924 treatment caused the higher-molecular-weight band
corresponding to NEDDylated CUL2 to collapse and led to con-
current HIF1a stabilization compared with DMSO-treated con-
trols (Figures 2E and 2F). Under these conditions in FLAG-
aGFP6M-Halo-expressing cells, treatment with MLN4924
partially prevented the GFP-ULK1 (Figure 2E) and FAM83D-
GFP (Figure 2F) degradation caused by HaloPROTAC-E. Inter-
estingly, FAM83D-GFP levels were slightly destabilized with
MLN4924 in the absence of HaloPROTAC-E (Figure 2F), sug-
gesting that endogenous FAM83D expression is potentially
regulated by a set of factors that may be dysregulated upon
CUL-CRL inhibition (Xu et al., 2018). To assess whether GFP-
Figure 2. Characterization of HaloPROTAC-E L-AdPROM-Mediated GFP-ULK1 and FAM83D-GFP Degradation
(A and B) ARPE-19 ULK1GFP/GFP (A) or U2OS FAM83DGFP/GFP (B) FLAG-empty, FLAG-aGFP6M-Halo and FLAG-aGFP6M-Halo
D106A binding mutant-expressing
cells were treated with 250 nM (A) or 1 mM (B) HaloPROTAC-E for 24 h.
(C and D) ARPE-19ULK1GFP/GFP (C) or U2OS FAM83DGFP/GFP (D) FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were treatedwith 250 nM (C) or 1 mM (D)
HaloPROTAC-E and 50 mM VHL inhibitor VH298 for 24 h.
(E and F) ARPE-19 ULK1GFP/GFP (E) or U2OS FAM83DGFP/GFP (F) FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were treated with 250 nM (E) or 1 mM (F)
HaloPROTAC-E and 1 mM pan-Cullin NEDDylation inhibitor MLN4924 for 24 h.
(G andH) ARPE-19ULK1GFP/GFP (G) or U2OS FAM83DGFP/GFP (H) FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were treatedwith 250 nM (G) or 1 mM (H)
HaloPROTAC-E and 20 mM proteasome inhibitor MG132 for 24 h.
For (A)–(H), extracts were resolved by SDS-PAGE and transferred on to PVDF membranes, which were subjected to immunoblotting with indicated antibodies.
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proteasomal degradation, the proteasome inhibitor MG132
was utilized (Figures 2G and 2H). In FLAG-aGFP6M-Halo-ex-
pressing cells, treatment with MG132 partially prevented the
GFP-ULK1 (Figure 2G) and FAM83D-GFP (Figure 2H) degrada-
tion caused by HaloPROTAC-E. As with MLN4924 treatment,
FAM83D-GFP levels were slightly destabilized with MG132 in
the absence of HaloPROTAC-E (Figure 2H), suggesting that
endogenous FAM83D expression is potentially regulated by a
set of factors that may be dysregulated upon proteasomal
inhibition.
HaloPROTAC-E L-AdPROM-Mediated Degradation of
SGK3-GFP Is Comparable to that with SGK3-PROTAC1
SGK3 is a PX domain containing protein kinase that is activated
at endosomes by the class 1 and 3 phosphatidylinositol 3-ki-
nase (PI3K) family members in response to growth factors or
oncogenic mutations (Bago et al., 2016; Malik et al., 2018).
SGK3 is involved in the resistance to class 1 PI3K or Akt inhib-
itors in breast cancer as SGK3 can substitute for the loss of Akt
activity and restore proliferation (Bago et al., 2016; Tovell et al.,
2019b). HaloPROTAC-E was developed for the inducible
degradation of SGK3, which was knocked in with a Halo-tag
on one allele while another allele silenced in HEK293 cells
(SGK3Halo/) (Tovell et al., 2019a). We used HEK293 SGK3
GFP KI (SGK3GFP/GFP) cells (Malik et al., 2018) to test HaloPRO-
TAC-E L-AdPROM-mediated degradation of SGK3-GFP. When
SGK3GFP/GFP cell extracts expressing FLAG-empty control,
FLAG-Halo-aGFP6M, or FLAG-aGFP6M-Halo were subjected
to anti-FLAG IP, SGK3-GFP co-precipitated only with FLAG-
Halo-aGFP6M and FLAG-aGFP6M-Halo (Figure S4A). Treatment
of SGK3GFP/GFP FLAG-empty control, FLAG-Halo-aGFP6M (Fig-
ure S4B), and FLAG-aGFP6M-Halo (Figure S4C) expressing
cells with increasing concentrations of HaloPROTAC-E (0.1–
2 mM) for 24 h led to a reduction in SGK3-GFP levels only in
cells expressing FLAG-Halo-aGFP6M (Figure S4B) or FLAG-
aGFP6M-Halo (Figure S4C), with optimal degradation achieved
with 250 nM HaloPROTAC-E.
Next, we compared HaloPROTAC-E-mediated SGK3-Halo
degradation in SGK3Halo/ cells against SGK3-GFP degradation
in SGK3GFP/GFP L-AdPROM-expressing cells. HEK293 WT,
SGK3Halo/, and SGK3GFP/GFP FLAG-empty, FLAG-Halo-
aGFP6M, and FLAG-aGFP6M-Halo-expressing cells were treated
with 250 nM HaloPROTAC-E for 24 h (Figures 3A and 3B). No
changes in SGK3 or SGK3-GFP levels were observed in Halo-
PROTAC-E-treated WT or SGK3GFP/GFP cells, respectively.
However, similar levels of SGK3-Halo and SGK3-GFP degrada-
tion was observed in HaloPROTAC-E-treated SGK3Halo/ and
SGK3GFP/GFP cells expressing FLAG-Halo-aGFP6M or FLAG-
aGFP6M-Halo, respectively. To compare HaloPROTAC-E-medi-
ated SGK3-Halo and SGK3-GFP degradation kinetics,
SGK3Halo/ cells or SGK3GFP/GFP cells expressing FLAG-Halo-
aGFP6M or FLAG-aGFP6M-Halo were treated with 250 nM Halo-
PROTAC-E for 3, 6, and 24 h (Figures 3C and 3D). Although
SGK3-Halo degradation was achieved slightly earlier after Halo-
PROTAC-E treatment, no significant difference in SGK3 levels
were observed after 24 h in either SGK3Halo/ cells or L-Ad-
PROM-expressing SGK3GFP/GFP cells. These data suggest that
HaloPROTAC-E can be utilized both for the degradation of6 Cell Chemical Biology 27, 1–17, August 20, 2020POIs knocked in with a Halo-tag or with a GFP-tag using the L-
AdPROM system.
A potent SGK3-specific degrader, SGK3-PROTAC1, that
binds both SGK3 and VHLwas recently developed for the degra-
dation of endogenous SGK3 (Tovell et al., 2019b). To directly
compare SGK3-PROTAC1 with HaloPROTAC-E L-AdPROM-
mediated SGK3 degradation, HEK293 WT and SGK3GFP/GFP
FLAG-empty control, FLAG-Halo-aGFP6M, and FLAG-aGFP6M-
Halo-expressing cells were treated with 250 nM of either
SGK3-PROTAC1 or HaloPROTAC-E for 24 h (Figures 3E and
3F). As expected, no changes in SGK3 or SGK3-GFP levels
were observed with HaloPROTAC-E in WT or SGK3GFP/GFP
FLAG-empty cells, respectively, while degradation of both was
observed with SGK3-PROTAC1. Interestingly, similar levels of
SGK3-GFP degradation were observed with SGK3-PROTAC1
or HaloPROTAC-E in SGK3GFP/GFP cells expressing FLAG-
Halo-aGFP6M or FLAG-aGFP6M-Halo.
HaloPROTAC-E L-AdPROM-Mediated GFP-ULK1,
FAM83D-GFP, and SGK3-GFPDegradation Is Reversible
We have demonstrated that following the expression of the L-
AdPROM construct in cells harboring a POI-GFP, HaloPRO-
TAC-E treatment induces robust POI-GFP degradation (Figures
1, 2, and 3). For a truly tractable system, when HaloPROTAC-E is
removed, POI-GFP degradation should cease and stabilize
thereafter. Therefore, we wanted to determine the reversibility
of HaloPROTAC-E-mediated GFP-ULK1, FAM83D-GFP, and
SGK3-GFP degradation in ARPE-19 ULK1GFP/GFP (Figures 4A
and 4B), U2OS FAM83DGFP/GFP (Figures 4C and 4D), and
HEK293 SGK3GFP/GFP (Figures 4E and 4F) L-AdPROM-express-
ing cells, respectively. Cells were treated with or without Halo-
PROTAC-E for 24 h, washed with PBS to remove the compound
or maintained in the presence of HaloPROTAC-E, and POI-GFP
levels were assessed up to 48 h thereafter. Both GFP-ULK1 (Fig-
ures 4A and 4B) and FAM83D-GFP (Figures 4C and 4D) levels
were restored in a time-dependent manner reaching near control
levels after 24 h, and SGK3-GFP (Figures 4E and 4F) levels after
48 h. POI-GFP degradation was sustained at all time points in
cells that were maintained in HaloPROTAC-E. As expected, no
changes in POI-GFP levels were observed in DMSO-treated
controls following similar wash-out as HaloPROTAC-E. These
data suggest that HaloPROTAC-E-mediated POI-GFP degrada-
tion through the L-AdPROM system is reversible.
HaloPROTAC-E L-AdPROM-Mediated GFP-ULK1
Degradation Inhibits Starvation-Induced Autophagy
ULK1 functions in a complex with FIP200 (focal adhesion
kinase family interacting protein of 200 kDa) and ATG (auto-
phagy-relatedprotein) 13 (ATG13) for the regulation of autophagy
initiation (Ganley et al., 2009; Jung et al., 2009; Hosokawa et al.,
2009). To investigate whether the GFP-ULK1:ATG13:FIP200
interaction is affected following HaloPROTAC-E-mediated
GFP-ULK1 degradation, ARPE-19 ULK1GFP/GFP FLAG-empty
control and FLAG-aGFP6M-Halo-expressing cells were treated
with HaloPROTAC-E and subjected to anti-ATG13 IP (Figure 5A).
Both GFP-ULK1 and FIP200 co-precipitated with ATG13 in
ULK1GFP/GFP FLAG-empty and FLAG-aGFP6M-Halo-expressing
cells, suggesting that the expression of FLAG-aGFP6M-
Halo does not interfere with the interaction of GFP-ULK1
Figure 3. HaloPROTAC-E L-AdPROM-Mediated Degradation of SGK3-GFP Is Comparable to that with SGK3-PROTAC1
(A) HEK293WT, SGK3Halo/,SGK3GFP/GFP FLAG-empty, FLAG-Halo-aGFP6M and FLAG-aGFP6M-Halo-expressing cells were treated with 250 nMHaloPROTAC-
E for 24 h. Extracts were resolved by SDS-PAGE and transferred on to PVDF membranes, which were subjected to immunoblotting with indicated antibodies.
(B) Quantification of relative SGK3 protein levels from (A) normalized to loading control ± SD of n = 3 independent experiments.
(C) As in (A), except SGK3Halo/ and SGK3GFP/GFP FLAG-Halo-aGFP6M and FLAG-aGFP6M-Halo-expressing cells were treated with 250 nM HaloPROTAC-E for
indicated times.
(D) Quantification of relative SGK3 protein levels from (C) normalized to loading control ± SD of n = 3 independent experiments.
(E) As in (A), except HEK293 WT, SGK3GFP/GFP FLAG-empty, FLAG-Halo-aGFP6M, and FLAG-aGFP6M-Halo-expressing cells were treated with 250 nM SGK3-
PROTAC1 or HaloPROTAC-E for 24 h.
(F) Quantification of relative SGK3 protein levels from (E) normalized to loading control ± SD of n = 3 independent experiments.
Statistical analyses were carried out by one-way analysis of variance using Tukey’s post-test; n.s., not significant.
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FIP200 co-precipitated with ATG13 in HaloPROTAC-E-treated
ULK1GFP/GFPFLAG-empty cells, suggesting thatHaloPROTAC-E
itself does not interfere with the GFP-ULK1:ATG13:FIP200 inter-
action. Following HaloPROTAC-E-mediated GFP-ULK1 degra-dation in FLAG-aGFP6M-Halo cells, FIP200 but not GFP-ULK1
co-precipitated with ATG13, suggesting that ATG13 and
FIP200 can still interact in the absence of GFP-ULK1, consistent
with previous reports using RNAi-mediated depletion of ULK1
(Ganley et al., 2009).Cell Chemical Biology 27, 1–17, August 20, 2020 7
Figure 4. HaloPROTAC-E L-AdPROM-mediated GFP-ULK1, FAM83D-GFP, and SGK3-GFP Degradation Is Reversible
(A) ARPE-19 ULK1GFP/GFP FLAG-aGFP6M-Halo-expressing cells were treated with 250 nM HaloPROTAC-E for 24 h. Cells were then either washed three times
with PBS and medium replaced or maintained in the presence of HaloPROTAC-E and lysed after the indicated times. Extracts were resolved by SDS-PAGE and
transferred on to PVDF membranes, which were subjected to immunoblotting with indicated antibodies.
(B) Quantification of relative GFP-ULK1 protein levels from (A) normalized to GAPDH ± SD of n = 3 independent experiments.
(C) As in (A), except U2OS FAM83DGFP/GFP FLAG-aGFP6M-Halo-expressing cells were treated with 1 mM HaloPROTAC-E for 24 h.
(D) Quantification of relative FAM83D-GFP protein levels from (C) normalized to GAPDH ± SD of n = 3 independent experiments.
(E) As in (A), except HEK293 SGK3GFP/GFP FLAG-Halo-aGFP6M-expressing cells were treated with 250 nM HaloPROTAC-E for 24 h.
(F) Quantification of relative SGK3-GFP protein levels from (E) normalized to GAPDH ±SD of n = 3 independent experiments.
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mycin complex 1 (mTORC1) phosphorylates ULK1 at multiple
sites, including S757, to inhibit autophagy (Kim et al., 2011). Dur-
ing periods of nutrient deprivation, mTORC1 is inactivated and
the inhibitory phosphorylations on ULK1 are removed, resulting
in increased ULK1 kinase activity (Ganley et al., 2009; Jung
et al., 2009; Hosokawa et al., 2009; Kim et al., 2011). This leads
to downstream autophagy signaling, including phosphorylation
of ATG13 at S318 by activated ULK1 (Joo et al., 2011), expansion
of the autophagosome, marked by LC3 lipidation (LC3-II), which
engulfs cargo and then fuses with the lysosome for cargo degra-
dation (Zachari and Ganley, 2017). To investigate the effects of8 Cell Chemical Biology 27, 1–17, August 20, 2020HaloPROTAC-E L-AdPROM-mediated GFP-ULK1 degradation
on downstream starvation-induced autophagy signaling, Halo-
PROTAC-E-treated FLAG-aGFP6M-Halo-expressing ARPE-19
ULK1GFP/GFP cells were starved of amino acids for 2 h with
Earle’s balanced salt solution (EBSS) (Figure 5B). During this
period, cells were also treated either with or without Bafilomy-
cin-A1 (Baf-A1), which inhibits lysosomal degradation and pre-
vents autophagosome clearance. The resultant accumulation
of LC3-II can be used to monitor autophagic flux (Yoshimori
et al., 1991; Mauvezin et al., 2015; Klionsky et al., 2016). In
both EBSS-treated ULK1GFP/GFP FLAG-empty control and
FLAG-aGFP6M-Halo-expressing cells, a similar reduction in
Figure 5. HaloPROTAC-E L-AdPROM-mediated GFP-ULK1 Degradation Inhibits Starvation-Induced Autophagy
(A) ARPE-19 ULK1GFP/GFP FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were treated with 250 nM HaloPROTAC-E for 24 h and subjected to ATG13 or
IgG IP.
(legend continued on next page)
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indicating inhibition of mTOR. In addition, ATG13 phosphoryla-
tion at S318 also increased, demonstrating concomitant
activation of GFP-ULK1 and confirming that the expression of
FLAG-aGFP6M-Halo does not interfere with GFP-ULK1 regula-
tion during starvation-induced autophagy (Figures 5B and 5C).
However, following HaloPROTAC-E-mediated GFP-ULK1
degradation, the EBSS-induced increase in ATG13 phosphory-
lation was attenuated (Figures 5B and 5C), demonstrating that
HaloPROTAC-E L-AdPROM-mediated GFP-ULK1 degradation
blocks downstream GFP-ULK1 signaling. Importantly, this re-
sults in the inhibition of starvation-induced autophagy, as indi-
cated by the large reduction in LC3-II flux that occurs in
ULK1GFP/GFP FLAG-aGFP6M-Halo-expressing cells in the pres-
ence of HaloPROTAC-E compared with DMSO-treated and
FLAG-empty controls (Figures 5B and 5D).
Next, we wanted to compare the efficacy of GFP-ULK1 degra-
dation to inhibition by the small-molecule ULK1 inhibitors
MRT68921 (Petherick et al., 2015) and SBI-0206965 (Egan
et al., 2015). ARPE-19 ULK1GFP/GFP FLAG-aGFP6M-Halo-ex-
pressing cells were pre-treated with either HaloPROTAC-E,
MRT68921, or SBI-0206965, followed by EBSS and Baf-A1 for
2 h (Figure 5E). Under starvation conditions, the reduction in
ATG13 phosphorylation at Ser318 relative to untreated controls
was comparable between HaloPROTAC-E- and SBI-0206965-
treated cells (Figures 5E and 5F). ATG13 phosphorylation was
reduced further in MRT68921-treated cells (Figures 5E and 5F),
potentially due to the increased potency of MRT68921
compared with SBI-0206965 (Petherick et al., 2015; Egan
et al., 2015). However, under starvation conditions, LC3-II levels
were comparable between HaloPROTAC-E-, MRT68921-, and
SBI-0206965-treated cells (Figures 5E and 5G). These data sug-
gest that the attenuation of starvation-induced autophagy
observed following HaloPROTAC-E L-AdPROM-mediated
GFP-ULK1 degradation reflects that of small-molecule
inhibition.
HaloPROTAC-E L-AdPROM-Mediated FAM83D-GFP
Degradation Prevents CK1a Recruitment to the Mitotic
Spindle during Mitosis
Recently, we reported that FAM83D interacts with and
delivers CK1a to the mitotic spindle (Fulcher et al., 2019). In
both WT U2OS cells and those knocked in homozygously
with both FAM83D-GFP and mCherry (mCh)-CK1a
(FAM83DGFP/GFPCSNK1A1mCh/mCh), FAM83Dwasshown todirect
CK1a to the mitotic spindle for proper spindle positioning and
timely cell division (Fulcher et al., 2019). However in FAM83D-KO
cells, generated using CRISPR/Cas9, CK1a is no longer recruited
to the mitotic spindle, resulting in pronounced spindle positioning(B) ARPE-19ULK1GFP/GFP FLAG-empty and FLAG-aGFP6M-Halo-expressing cells
or 50 nM Bafilomycin-A1 (Baf-A1) for 2 h.
(C and D) Quantification of (C) p-S318 ATG13 normalized to total ATG13 protein le
independent experiments. +AA indicates amino acid-rich conditions.
(E) ARPE-19 ULK1GFP/GFP FLAG-aGFP6M-Halo-expressing cells were pre-treated
(2 mM) or SBI-0206965 (5 mM) for 2 h followed by either EBSS or 50 nM Baf-A1 f
(F and G) Quantification of (F) p-S318 ATG13 normalized to total ATG13 protein le
independent experiments.
Statistical analyses were carried out by one-way analysis of variance using Tukey
and transferred on to PVDF membranes, which were subjected to immunoblottin
10 Cell Chemical Biology 27, 1–17, August 20, 2020defects and a prolonged cell division (Fulcher et al., 2019). We
sought to investigate whether HaloPROTAC-E L-AdPROM-medi-
ated degradation of FAM83D-GFP from FAM83DGFP/GFPCSN-
K1A1mCh/mCh cells affects recruitment ofmCh-CK1a to themitotic
spindle. First, we tested whether the mitotic interaction between
FAM83D-GFP andmCh-CK1awas affected following the expres-
sion of FLAG-aGFP6M-Halo in FAM83D
GFP/GFPCSNK1A1mCh/mCh
cells, which were synchronized in mitosis using the Eg5 inhibitor
S-trityl-L-cysteine (STLC) (Fulcher et al., 2019) (Figure 6A). Anti-
GFP IPs from both FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-
empty control and FLAG-aGFP6M-Halo-expressing cells both
co-precipitated mCh-CK1a in mitotic but not asynchronous ex-
tracts (Figure6A), suggesting that FLAG-aGFP6M-Halo expression
alonedoesnot interferewith themitotic FAM83D-GFP:mCh-CK1a
interaction. As predicted, anti-GFP IPs from asynchronous or
mitotic WT extracts did not pull down FAM83D or CK1a. Next,
when FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-empty control
and FLAG-aGFP6M-Halo-expressing cells were treated with
1 mMHaloPROTAC-E for 24 h, a reduction in FAM83D-GFP levels
was observed only in cells expressing FLAG-aGFP6M-Halo (Fig-
ure 6B),while nodegradationofmCh-CK1awasobserved ineither
cell lines. To investigate the localization of FAM83D-GFP and
mCh-CK1a at the mitotic spindle following HaloPROTAC-E L-Ad-
PROM-mediated FAM83D-GFP degradation, WT and
FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-empty, and FLAG-
aGFP6M-Halo-expressing cells treated with HaloPROTAC-E
were synchronized using STLC, fixed, and analyzed by anti-FLAG
immunostaining andGFPandmChfluorescencemicroscopy (Fig-
ure 6C). FAM83D-GFP, mCh-CK1a, and FLAG-aGFP6M-Halo
localized at the mitotic spindle in FAM83DGFP/GFPCSN-
K1A1mCh/mCh cells expressing FLAG-aGFP6M-Halo, while these
mitotic localization signals were abolished with HaloPROTAC-E
(Figures 6C and 6D), suggesting that the recruitment of mCh-
CK1a to the mitotic spindle is inhibited by targeted degradation
of FAM83D-GFP through theHaloPROTAC-EL-AdPROMsystem.
Nochange inmCh-CK1amitotic spindle localizationwasobserved
in HaloPROTAC-E-treated FAM83DGFP/GFPCSNK1A1mCh/mCh
FLAG-empty control cells compared with DMSO-treated controls
or DMSO-treated FLAG-aGFP6M-Halo-expressing cells (Figures
6C and 6D). These data suggest that HaloPROTAC-E alone or
the expression of FLAG-aGFP6M-Halo in U2OS FAM83D
GFP/GFP
CSNK1A1mCh/mCh cells does not interferewith themitotic localiza-
tion of either FAM83D-GFP or mCh-CK1a.
Untagged Endogenous RAS Proteins Are Degraded with
HaloPROTAC-E in Cells Expressing FLAG-Halo-aHRAS
The proof-of-concept degradation of multiple POI-GFP KI pro-
teins through the aGFP6M L-AdPROM with HaloPROTAC-E
suggested that endogenous untagged POIs could be targetedwere pre-treatedwith 250 nMHaloPROTAC-E for 24 h followed by either EBSS
vels and (D) LC3-II protein levels normalized to a-tubulin from (B) ± SD of n = 3
with 250 nM HaloPROTAC-E for 24 h or with the ULK1 inhibitors MRT68921
or 2 h.
vels and (G) LC3-II protein levels normalized to a-tubulin from (E) ± SD of n = 3
’s post-test. For (A), (B), and (E), extracts and IPs were resolved by SDS-PAGE
g with indicated antibodies.
Figure 6. HaloPROTAC-E L-AdPROM-Mediated FAM83D-GFPDegradation Prevents CK1aRecruitment to theMitotic Spindle duringMitosis
(A) U2OSWT, FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were synchronized in mitosis using the Eg5 inhibitor S-
trityl-L-cysteine (STLC) (5 mM) for 16 h. Following incubation,mitotic (M) cells were isolated through shake-off. Asynchronous (AS) cells were included as a control.
Cells were washed twice with ice-cold PBS, lysed and subjected to anti-GFP IP.
(B) U2OS FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were treated with 1 mMHaloPROTAC-E for 24 h. For (A) and
(B), extracts and IPs were resolved by SDS-PAGE and transferred on to PVDF membranes, which were subjected to immunoblotting with indicated antibodies.
(C) U2OS WT, FAM83DGFP/GFPCSNK1A1mCh/mCh FLAG-empty and FLAG-aGFP6M-Halo-expressing cells were pre-treated with 1 mM HaloPROTAC-E for 24 h,
synchronized inmitosis using STLC (5 mM, 16 h) and subjected to anti-FLAG immunofluorescence and GFP andmCherry (mCh) fluorescencemicroscopy. DNA is
stained with DAPI. Scale bars, 10 mm.
(D) Quantification of mCh-CK1a spindle localization for cells described in (C). Boxplot whiskers denote the minimum andmaximummeasured values. Themiddle
line represents the median, and the box ranges depict the 25th/75th percentiles.
Statistical analysis was carried out on indicated number of cells by one-way analysis of variance using Dunnett’s post-test, n = 2 independent experiments; n.s.,
not significant.
ll
OPEN ACCESSArticle
Please cite this article in press as: Simpson et al., Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System,
Cell Chemical Biology (2020), https://doi.org/10.1016/j.chembiol.2020.06.013for degradation by substituting aGFP6M with high-affinity
binders of endogenous POIs. In this context, an anti-H-RAS
monobody (aHRAS), which binds to and immunoprecipitates
both H- and K-RAS, but not N-RAS, has been reported previ-
ously (Spencer-Smith et al., 2017). The RAS GTPases,
including H-, K-, and N-RAS, represent the most common me-
diators of oncogenesis in humans (Cox et al., 2014; Hobbs
et al., 2016). Specifically, 20%–50% of non-small cell lung car-
cinomas (NSCLC) harbor K-RAS mutations (Marabese et al.,
2015; Forest et al., 2017; Jia et al., 2017). However, the thera-
peutic targeting of K-RAS, either by conventional pharmacolog-
ical inhibition (Cox et al., 2014; Papke and Der, 2017) or tar-
geted degradation (Zeng et al., 2020), has proven extremelychallenging. Recently, we conjugated aHRAS to VHL to
mediate constitutive RAS degradation following retroviral trans-
duction in A549 NSCLC cells (Ro¨th et al., 2019). By conjugating
aHRAS to the Halo-tag and tagging with a FLAG reporter, we
sought to develop an L-AdPROM system to degrade untagged
endogenous RAS proteins only in the presence of HaloPRO-
TAC-E (Figure 7A).
Following the expression of FLAG-aHRAS and FLAG-Halo-
aHRAS by retroviral transduction in WT A549 cells, which har-
bor the K-RASG12S mutation (COSMIC cell lines project),
cell extracts were subjected to anti-FLAG IP (Figure 7B). pan-
RAS only co-precipitated with anti-FLAG IPs from both FLAG-
aHRAS and FLAG-Halo-aHRAS-expressing cells and wasCell Chemical Biology 27, 1–17, August 20, 2020 11
(legend on next page)
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conjugation of aHRAS to Halo does not affect the ability of
aHRAS to interact with RAS proteins. Next, to assess Halo-
PROTAC-E-mediated RAS degradation in FLAG-Halo-aH-
RAS-expressing cells, cells were treated with increasing con-
centrations of HaloPROTAC-E (0.005–10 mM) for 24 h
(Figure 7C). A reduction in both panRAS and FLAG levels
was observed with 0.5, 5, and 10 mM HaloPROTAC-E. To
analyze RAS degradation kinetics in HaloPROTAC-E-treated
FLAG-Halo-aHRAS-expressing cells, cells were treated with
500 nM HaloPROTAC-E for 2, 4, 6, 24, and 48 h (Figure 7D).
Both panRAS and FLAG displayed time-dependent degrada-
tion upon treatment with HaloPROTAC-E in FLAG-Halo-aH-
RAS-expressing cells, with robust degradation achieved after
24 and 48 h. To assess whether HaloPROTAC-E L-AdPROM-
mediated RAS degradation was facilitated by the proteasome,
the proteasome inhibitor MG132 was utilized (Figure 7E). In
FLAG-Halo-aHRAS-expressing cells, treatment with MG132
partially prevented panRAS degradation with HaloPROTAC-
E, confirming that HaloPROTAC-E-mediated RAS degradation
in FLAG-Halo-aHRAS-expressing cells is proteasome-
dependent.
Activating K-RAS mutations are known to result in the upre-
gulation of signaling pathways involved in tumor cell growth
and survival, including the mitogen-activated protein kinase
(MAPK) and PI3K/Akt signaling pathways (Affolter et al., 2013;
Okudela et al., 2004; Ding et al., 2008). Following HaloPRO-
TAC-E-mediated RAS degradation in FLAG-Halo-aHRAS-ex-
pressing cells, we analyzed the status of basal MAPK and
PI3K/Akt pathway components, specifically the levels of
BRAF, EGFR p-Y1068, ERK1/2 p-T202/Y204, and Akt p-S473
(Figure 7F). Relative to untreated control cells, no significant
changes in levels of panRAS, BRAF, EGFR p-Y1068, ERK1/2
p-T202/Y204, or Akt p-S473 were observed in FLAG-aHRAS-
expressing cells after 24 h with HaloPROTAC-E (Figures 7F–
7K), suggesting that HaloPROTAC-E alone does not affect
MAPK or PI3K/Akt signaling. However, under these conditions,
significant reduction in panRAS, BRAF, EGFR p-Y1068, and
Akt p-S473 levels were observed in FLAG-Halo-aHRAS-ex-
pressing cells treated with HaloPROTAC-E for 24 h, although
ERK1/2 p-T202/Y204 levels did not change significantly (Fig-
ures 7F–7K). These data suggest that HaloPROTAC-E-medi-
ated RAS degradation in FLAG-Halo-aHRAS expressing A549
cells appears to reduce RAS-driven PI3K/Akt signaling
downstream.Figure 7. Untagged Endogenous RAS Proteins Are Degraded with Hal
(A) Schematic representation of FLAG-Halo-aHRAS HaloPROTAC L-AdPROM s
(B) A549 FLAG-empty, FLAG-aHRAS, and FLAG-Halo-aHRAS-expressing cells
through extract.
(C) A549 FLAG-Halo-aHRAS-expressing cells were treated with increasing conc
(D) A549 FLAG-Halo-aHRAS-expressing cells were treated with 500 nM HaloPR
(E) A549 FLAG-Halo-aHRAS-expressing cells were treated with 500 nM HaloPRO
(F) A549 FLAG-aHRAS and FLAG-Halo-aHRAS-expressing cells were treated wi
For (B–F), extracts and IPs were resolved by SDS-PAGE and transferred on to
antibodies.
(G–K) Quantification from (F) of relative (G) panRAS normalized to GAPDH protein
p-Y1068 EGFR normalized to total EGFR protein levels (n = 6 ± SD), (J) p-T202/Y20
Akt normalized to total Akt protein levels (n = 6 ± SD) in the absence or presenc
Statistical analyses were carried out by one-way analysis of variance using TukeDISCUSSION
In this report, we have combined the use of polypeptide binders
of specific POIs with a HaloPROTAC to engineer a tractable L-
AdPROM system for inducible degradation of POIs. We utilized
L-AdPROM to mediate the inducible degradation of endoge-
nously GFP-tagged ULK1, FAM83D, and SGK3 in ARPE-19,
U2OS, and HEK293 cells, respectively, after treatment with a
HaloPROTAC. While degradation of target proteins was not
complete, this seems to be a limitation of targeted proteolysis
in general, as SGK3 was degraded to a similar degree with
both HaloPROTAC L-AdPROM and SGK3-PROTAC1. Crucially,
the level of degradation achieved for GFP-ULK1 using the Halo-
PROTAC L-AdPROMsystemwas sufficient to inhibit the function
of GFP-ULK1 in the initiation of starvation-induced autophagy.
Similarly, FAM83D-GFP degradation led to the inhibition of
CK1a recruitment to the mitotic spindle. However, it is important
to note that, as with any RNA/protein knockdown approach, the
impact on specific POI biological function may vary depending
on the level of POI degradation achieved.
HaloPROTACs are already being used for the degradation of
POIs where the Halo-tag is introduced with CRISPR/Cas9
genome editing (Tovell et al., 2019a), similar to how GFP-tags
were introduced on our targets. Our HaloPROTAC L-AdPROM
system offers an alternative to tagging POIs with Halo for tar-
geted POI degradation. In addition, for any existing POI-GFP
KI cell lines, which are routinely generated for immunofluores-
cence and proteomics applications, or for those POIs for which
polypeptide binders exist, our L-AdPROM system serves as a
readymade tool for dissecting the biological consequences of
POI degradation.
The level of SGK3-GFP degradation achieved using the Halo-
PROTAC L-AdPROM system was similar to that achieved with a
potent SGK3-specific PROTAC. In principle, the L-AdPROM
system can thus be exploited not only to explore the biological
role of the POI but also rapidly validate the phenotypic effects
of UPS-mediated POI degradation, before the development of
more resource-intensive POI-specific PROTACs. It is important
to note that the ubiquitylation sites on POIs caused by POI-spe-
cific PROTACs and L-AdPROM are likely to be different, but the
information on the phenotypic consequences resulting from the
levels of POI degradation achieved is nonetheless valuable. The
principle for recruitment of a promiscuous E3 ligase to ubiquity-
late POIs is at the heart of both PROTACs and L-AdPROM, and
as long as POIs are degraded by the UPS, determining whichoPROTAC-E in Cells Expressing FLAG-Halo-aHRAS
ystem.
were lysed and subjected to IP with anti-FLAG M2 resin. F.T., post-IP flow-
entrations of HaloPROTAC-E (0–10 mM) for 24 h.
OTAC-E for indicated times (0–48 h).
TAC-E and 20 mM proteasome inhibitor MG132 for 24 h.
th 500 nM HaloPROTAC-E for indicated times (0, 3, 6, and 24 h).
PVDF membranes, which were subjected to immunoblotting with indicated
levels (n = 6 ± SD), (H) BRAF normalized to GAPDH protein levels (n = 3 ± SD), (I)
4 ERK1/2 normalized to total ERK1/2 protein levels (n = 6 ± SD), and (K) p-S473
e of HaloPROTAC-E (500 nM, 24 h).
y’s post-test.
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does not necessarily inform a uniform mode of action. However,
in certain cases with tagged POIs, the ubiquitylation of the tag it-
self can be sufficient to cause the fused POI to be degraded, as
was recently exemplified (Zeng et al., 2020).
The L-AdPROM has two crucial interlinked components: the
Halo-tag, which binds the HaloPROTAC, and the POI-specific
polypeptide binder, which binds the target POI. In principle,
the polypeptide binder can be substituted for any high-affinity
POI-specific binder and the resulting L-AdPROM system
should target the POI for degradation only upon treatment of
cells with the HaloPROTAC. In theory, this approach could
then be applied to any cell systems without the need for
CRISPR/Cas9 genome editing to introduce GFP- or Halo-tags
on POIs. For proof-of-principle, we substituted the anti-GFP
nanobody for a monobody that specifically binds H- and K-
RAS and achieved degradation of unmodified endogenous
RAS proteins only in the presence of the HaloPROTAC. The
level of RAS degradation achieved in the presence of Halo-
PROTAC-E in FLAG-Halo-aHRAS expressing A549 cells was
sufficient to reduce RAS-driven signaling downstream. Ideally,
the development of high-affinity polypeptide binders with a
higher degree of specificity, for example, a K-RASG12C-specific
binder, needs to be explored to further expand the capability of
this approach.
The benefits of PROTAC technologies over conventional
small-molecule inhibitors, such as the capability of PROTACs
to specifically reduce target protein levels at nanomolar con-
centrations (Bondeson and Crews, 2017; Lucas and Ciulli,
2017) as well as eliminating the scaffolding role of the protein
(Burslem et al., 2018), can be harnessed with our L-AdPROM
system. Currently the optimal inhibition of ULK1 using specif-
ically designed small-molecule inhibitors still requires com-
pound concentrations ranging from 1 to 10 mM (Petherick
et al., 2015; Egan et al., 2015; Martin et al., 2018; Zachari
et al., 2020). We observed that the attenuation in starvation-
induced autophagy following GFP-ULK1 degradation with
250 nM HaloPROTAC-E reflects that of GFP-ULK1 inhibition
using MRT68921 or SBI-0206965. As well as ULK1,
MRT68921 (Petherick et al., 2015) and SBI-0206965 (Martin
et al., 2018; Dite et al., 2018) have been reported to also inhibit
a number of additional kinases. Therefore, the employment of a
targeted protein degradation approach, such as the L-Ad-
PROM system, can potentially overcome off-target effects
observed with conventional pharmacological inhibitors, in addi-
tion to eliminating the potential scaffolding roles the protein ki-
nases may also perform.
One concern with regard to the utilization of the L-AdPROM
system is that the introduction and expression of a 48-kDa com-
plex might negatively interfere with the biological function of the
POI. Although we observe slight POI-GFP stabilization following
the expression of FLAG-aGFP6M-Halo, expression in ARPE-19
ULK1GFP/GFP or U2OS FAM83DGFP/GFPCSNK1A1mCh/mCh cells
did not appear to interfere with GFP-ULK1 or FAM83D-GFP
functions, respectively. Nonetheless, potential impact on POI
function needs to be evaluated on a case-by-case basis.
Following the expression of FLAG-aGFP6M-Halo in U2OS
FAM83DGFP/GFPCSNK1A1mCh/mCh cells, no stabilization of
mCh-CK1a was observed, nor were there any changes in14 Cell Chemical Biology 27, 1–17, August 20, 2020mCh-CK1a levels with HaloPROTAC-E, while FAM83D-GFP
was robustly degraded. To fully ascertain potential off-target ef-
fects of the L-AdPROM system, a quantitative proteomics
approach could be used to determine the potential changes in
stability of other proteins following the expression of FLAG-
aGFP6M-Halo and/or with HaloPROTAC-E.
The L-AdPROM system presented here further expands on
the currently available targeted protein degradation technolo-
gies that can be exploited, each possessing their own benefits
and limitations (Roth et al., 2019). The auxin-inducible degron
(AID) system, for example, achieves rapid degradation of POIs
either knocked in with the AID (Natsume et al., 2016) or of
GFP-tagged POIs following the expression of AID fused to an
anti-GFP nanobody (Daniel et al., 2018) in the presence of
indole-3-acetic acid (IAA). However, for use in mammalian cells,
the AID system also requires the overexpression of the plant-
based F box transport inhibitor response 1 (TIR1) protein.
Furthermore, relatively large IAA concentrations of 500 mM are
required to induce POI degradation in cells (Natsume et al.,
2016; Daniel et al., 2018), which has been reported to be toxic
at high concentrations due to IAA oxidation by eukaryotic perox-
idases (Folkes et al., 1999). In contrast, no effect on cell viability
was reported by MTS assay in WT HEK293 cells treated with
0.001–1 mM HaloPROTAC-E for 48 h (Tovell et al., 2019a). In
addition, the dTAG system (Nabet et al., 2018) exploited a stable
FKBP12 mutant, FKBP12F36V, which contains a ligand-binding
cavity, to develop a FKBP12F36V-CRBN-based PROTAC,
dTAG-13. Using CRISPR/Cas9 to tag a POI with FKBP12F36V
(POI-FKBP12F36V), POI-FKBP12F36V degradation through the
CUL4-CRL machinery was observed in the presence of dTAG-
13 at nanomolar concentrations. FKBP12F36V is a smaller tag
than Halo and uses a non-covalent ligand. Therefore, an L-Ad-
PROM system which substitutes Halo for FKBP12F36V, conju-
gated to a high-affinity small polypeptide binder, may prove a
viable option for dTAG-13-mediated POI degradation, where
the homozygous integration of a non-fluorescent FKBP12F36V-
tag using CRISPR/Cas9 is not feasible.
SIGNIFICANCE
A ligand-inducible affinity-directed protein missile (L-Ad-
PROM) technology for tractable and reversible degradation
of desired intracellular proteins of interest (POIs) is
described. We demonstrate that targeted POI degradation
using the L-AdPROM system leads to loss of protein func-
tion. The L-AdPROM technology is versatile and adaptable,
where, in principle, the small polypeptide binder can be
substituted for any high-affinity POI-targeting binder. There-
fore, this technology offers an excellent opportunity for any
researcher wishing to dissect the function of potentially any
intracellular POI. Targeted degradation of POIs potentially
overcomes the key limitations of CRISPR/Cas9-mediated
gene knockouts, which are irreversible and not possible
when targeting essential genes, as well as RNA interference
approaches, which often require prolonged treatments and
are commonly associated with off-target effects. Our tech-
nology can be exploited to rapidly inform the utility of UPS-
mediated POI degradation before the resource-intensive
and lengthy development of POI-specific PROTACs.
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Mouse monoclonal anti-Akt p-S473 Cell Signaling Technology Cat# 12694, RRID:AB_2797994
Rabbit polyclonal anti-ATG13 Sigma-Aldrich Cat# SAB4200100, RRID:AB_10602787
Sheep polyclonal anti-ATG13 MRC PPU Reagents & Services Cat# S777C
Rabbit polyclonal anti-ATG13 p-S318 Novus Cat# NBP2-19127
Rabbit monoclonal anti-BRAF Thermo Fisher Scientific Cat# 702187, RRID:AB_2633065
Rabbit polyclonal anti-CK1a Bethyl Cat# A301-991A RRID:AB_1576501
Sheep polyclonal anti-CK1a MRC PPU Reagents & Services Cat# SA527
Rabbit polyclonal anti-CUL2 Invitrogen Cat# 51-1800, RRID:AB_2533898
Rabbit polyclonal anti-EGFR Santa Cruz Biotechnology Cat# sc-03, RRID:AB_631420
Rabbit monoclonal anti-EGFR p-Y1068 Cell Signaling Technology Cat# 3777, RRID:AB_2096270
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T202/Y204
Cell Signaling Technology Cat# 9106, RRID:AB_331768
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Rabbit polyclonal anti-FIP200 Proteintech Cat# 17250-1-AP, RRID:AB_10666428
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Sigma-Aldrich Cat# A8592, RRID:AB_439702
Mouse monoclonal anti-FLAG Sigma-Aldrich Cat# F1804, RRID:AB_262044
Rabbit monoclonal anti-GAPDH Cell Signaling Technology Cat# 2118, RRID:AB_561053
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Mouse monoclonal anti-HIF1a BD Biosciences Cat# 610959, RRID:AB_398272
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Goat anti-rabbit IgG HRP-conjugated Cell Signaling Technology Cat# 7074, RRID:AB_2099233
Rabbit anti-sheep IgG HRP-conjugated Thermo Fisher Scientific Cat# 31480, RRID:AB_228457
Goat anti-rat IgG HRP-conjugated Thermo Fisher Scientific Cat# 62-9520, RRID:AB_2533965
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Goat-anti-mouse IgG Alexa-Fluor 647 Thermo Fisher Scientific Cat# A-21235
Chemicals, Peptides, and Recombinant Proteins
HaloPROTAC-E Tovell et al. 2019a N/A
SGK3-PROTAC1 Tovell et al. 2019b N/A
VH298 Frost et al. 2016 N/A
MLN4924 Active Biochem Cat# A-1139
MG132 Abcam Cat# Ab141003
Bafilomycin-A1 Enzo Life Sciences Cat# BML-CM110
MRT68921 MRC PPU Reagents & Services N/A
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SBI-0206965 Sigma-Aldrich Cat# SML1540
S-trityl-L-cysteine (STLC) Sigma-Aldrich Cat# 164739
PEI MAX – Transfection Grade Linear PEI
Hydrochloride MW 40,000
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Polybrene (Hexadimethrine bromide) Sigma-Aldrich Cat# 107689
GFP-Trap-Agarose Chromotek Cat# GTA-20
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Immobilon Western Chemiluminescent
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ProLong Gold Antifade Mountant
with DAPI
Life Technologies Cat# P36935
Deposited Data
Data obtained in this study This paper https://data.mendeley.com/datasets/
xjnf2sr577/draft?a=4dd608f3-a50c-42af-
bd0f-2d470e6b0ef0
Experimental Models: Cell Lines
A549 ATCC Cat# CCL-185
ARPE-19 ATCC Cat# CRL-2302
ARPE-19 ULK1GFP/GFP This paper N/A
HEK293 ATCC Cat# CRL-1573
HEK293 SGK3Halo/- Tovell et al. 2019a N/A
HEK293 SGK3GFP/GFP Malik et al. 2018 N/A
HEK293-FT Invitrogen Cat# R70007
U2OS ATCC Cat# HTB-96
U2OS FAM83DGFP/GFP Fulcher et al. 2019 N/A
U2OS FAM83DGFP/GFPCSNK1A1mCh/mCh Fulcher et al. 2019 N/A
Recombinant DNA
pCMV-gag-pol Cell Biolabs Cat# RV-111
pCMV-VSV-G Cell Biolabs Cat# RV-110
pBabeD-puromycin FLAG-Halo-aGFP6M This paper; MRC PPU Reagents & Services Cat# DU57764
pBabeD-puromycin FLAG-aGFP6M-Halo This paper; MRC PPU Reagents & Services Cat# DU57765
pBabeD-puromycin FLAG-aGFP6M-
HaloD106A
This paper; MRC PPU Reagents & Services Cat# DU60748
pBabeD-puromycin FLAG-aHRAS MRC PPU Reagents & Services Cat# DU57190
pBabeD-puromycin FLAG-Halo-aHRAS This paper; MRC PPU Reagents & Services Cat# DU57462
pBabeD-puromycin GFP MRC PPU Reagents & Services Cat# DU32961
pBabeD-puromycin U6 ULK1 N-terminal
knockin (KI) Sense guide RNA (gRNA)
This paper; MRC PPU Reagents & Services Cat# DU57396
pX335 ULK1 N-terminal knockin (KI)
Antisense guide RNA (gRNA) + Cas9n
This paper; MRC PPU Reagents & Services Cat# DU57403
pMA-RQ ULK1 N-terminal GFP donor This paper; MRC PPU Reagents & Services Cat# DU57856
Software and Algorithms
ImageJ Schneider et al. 2012 https://imagej.nih.gov/ij/
SoftWoRx GE Healthcare N/A
OMERO Allan et al., 2012 http://openmicroscopy.org/
Graphpad Prism v8 GraphPad Prism Inc https://www.graphpad.com/scientific-
software/prism/
CK1a spindle localisation
quantification macro
Fulcher et al. 2019 N/A
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gopal
Sapkota (g.sapkota@dundee.ac.uk).
Materials Availability
All constructs used in this study are available to request from the MRC PPU Reagents & Services webpage (http://mrcppureagents.
dundee.ac.uk) and the unique identifier (DU) numbers provide direct links to the cloning strategies and sequence details. All con-
structs were sequence-verified by the DNA Sequencing Service, University of Dundee (http://www.dnaseq.co.uk).
Data and Code Availability
The datasets generated during this study are available at Mendeley Data https://data.mendeley.com/datasets/xjnf2sr577/draft?
a=4dd608f3-a50c-42af-bd0f-2d470e6b0ef0.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
All procedures were carried out under aseptic conditions meeting biological safety requirements. A549 cells (ATCC, Cat# CCL-185)
are human epithelial lung carcinoma cells derived from a 58-year-old Caucasian male. ARPE-19 cells (ATCC, Cat# CRL-2302) are
human retinal pigment epithelial cells derived from a 19-year-old male. HEK293 cells (ATCC, Cat# CRL-1573) are human embryonic
kidney cells. HEK293-FT cells (Invitrogen, Cat# R70007) are a clonal isolate of HEK293 cells transformed with the SV40 large T an-
tigen. U2OS cells (ATCC, Cat# HTB-96) are human epithelial bone osteosarcoma cells derived from a 15-year-old Caucasian female.
For growth, A549, HEK293, HEK293-FT and U2OS cells were maintained in DMEM (Life Technologies) containing 10% (v/v) foetal
bovine serum (FBS, Thermo Fisher Scientific), 2 mM L-glutamine (Lonza), 100 U/ml penicillin (Lonza) and 0.1 mg/ml streptomycin
(Lonza). ARPE-19 cells were maintained in a 1:1 mix of DMEM and Ham’s F-12 nutrient mix (Life Technologies) containing 15%
(v/v) FBS, 2mML-glutamine, 100 U/ml penicillin and 0.1mg/ml streptomycin. Cells were grown at 37Cwith 5%CO2 in awater-satu-
rated incubator. For passaging, cells were incubatedwith trypsin/EDTA at 37C to detach cells. For transient transfections, cells were
transfected for 24 hr with indicated concentration of cDNA (per 10 ml media) in serum free Opti-MEM (Gibco) with the transfection
reagent polyethylenimine (PEI; diluted in 25 mM HEPES pH 7.5).
METHOD DETAILS
Plasmids
For transient expression or production of retroviral vectors, the following were cloned into pBABED-puromycin plasmids: FLAG-
Halo-aGFP6M (DU57764), FLAG-aGFP6M-Halo (DU57765), FLAG-aGFP6M-Halo
D106A (DU60748), FLAG-aHRAS (DU57190), FLAG-
Halo-aHRAS (DU57462), GFP (DU32961). For the generation of ARPE-19 ULK1GFP/GFP cells, the following guide RNAs (gRNA)
and donor constructs were generated: sense gRNA (DU57396), antisense gRNA (DU57403), GFP donor (DU57856). All constructs
were sequence-verified by the DNA Sequencing Service, University of Dundee (http://www.dnaseq.co.uk). These constructs are
available to request from the MRC PPU Reagents and Services webpage (http://mrcppureagents.dundee.ac.uk) and the unique
identifier (DU) numbers provide direct links to the cloning strategies and sequence details.
Generation of Cell Lines Using CRISPR/Cas9
The CRISPR/Cas9 genome editing system (Cong et al., 2013) was used to generate U2OS FAM83D homozygous C-terminal GFP
knockin (KI) (FAM83DGFP/GFP) cells (Fulcher et al., 2019), U2OS FAM83D homozygousC-terminal GFPKI andCSNK1A1 homozygous
N-terminal mCherry (mCh) KI (FAM83DGFP/GFPCSNK1A1mCh/mCh) cells (Fulcher et al., 2019), HEK293 SGK3 homozygous C-terminal
GFPKI (SGK3GFP/GFP) cells (Malik et al., 2018), HEK293 heterozygousSGK3C-terminal Halo KI (SGK3Halo/-) cells (Tovell et al., 2019a),
and ARPE-19 ULK1 homozygous N-terminal GFP KI (ULK1GFP/GFP) cells. For the generation of ARPE-19 ULK1GFP/GFP cells, cells
were transfected with vectors encoding a pair of guide RNAs (pBABED-puromycin-sgRNA1 and pX335-CAS9-D10A-sgRNA2) tar-
geting ULK1 exon 1 (1mg each), along with the respective donor plasmids carrying the GFPKI insert (3mg) and PEI. 16 hr post-trans-
fection, selection with 2 mg/ml puromycin (Sigma-Aldrich) was carried out and continued for a further 48 hr. The transfection process
was repeated one more time. After selection, cells were sorted by flow cytometry and single GFP-positive cell clones were plated on
individual wells of two 96-well plates. Viable clones were expanded, and integration of GFP at the target locus was verified by West-
ern blotting and genomic sequencing of the targeted locus.
Retroviral Generation of Stable Cell Lines
Retroviral pBABED-puromycin vectors encoding the desired construct (6 mg) were co-transfected with pCMV5-gag-pol (3.2 mg) and
pCMV5-VSV-G (2.8 mg) (Cell Biolabs) into a 10 cmdiameter dish of70%confluent HEK293-FT cells. Briefly, plasmidswere added to
1 ml Opti-MEM medium to which 24 ml of 1 mg/ml PEI was added. Following a gentle mix and incubation at room temperature fore3 Cell Chemical Biology 27, 1–17.e1–e5, August 20, 2020
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24 hr later, the retroviral mediumwas collected and passed through 0.45 mmsterile syringe filters. Target cells (60%confluent) were
transduced with the optimised titre of the retroviral medium diluted in fresh medium (typically 1:1-1:10) containing 8 mg/ml polybrene
(Sigma-Aldrich) for 24 hr. The retroviral medium was then replaced with fresh medium, and 24 hr later, the medium was again re-
placed with fresh medium containing 2 mg/ml puromycin for selection of cells which had integrated the constructs. A pool of trans-
duced cells were utilised for subsequent experiments following complete death of non-transduced cells placed under selection in
parallel.
Treatment of Cells with Compounds
HaloPROTAC-E, SGK3-PROTAC1 and VH298 were synthesised as previously described (Tovell et al., 2019a; Tovell et al., 2019b;
Frost et al., 2016) and used at indicated concentrations and times. The following chemicals were added to cell media at indicated
concentrations and times: MLN4924 (Active Biochem), MG132 (Abcam), Bafilomycin-A1 (Enzo Life Sciences), MRT68921 (MRC
PPU Reagents and Services), SBI-0206965 (Sigma-Aldrich). Cells were synchronised in mitosis using the Eg5 inhibitor S-trityl-L-
cysteine (STLC, Sigma-Aldrich, 5 mM, 16 hr) (Fulcher et al., 2019). Following incubation, mitotic cells were isolated through shake-
off. For amino acid starvation, cells were washed twice in Earle’s balanced salt solution (EBSS, Gibco) and incubated in EBSS for 2 hr.
Cell Lysis and Immunoprecipitation
Cells were harvested by washing twice with phosphate-buffered saline (PBS) and scraping into ice-cold lysis buffer (50 mM Tris-HCl
pH 7.5, 0.27 M sucrose, 150 mMNaCl, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium b-glycerophosphate,
50 mM sodium fluoride, 5 mM sodium pyrophosphate and 1% NP-40) supplemented with 1x cOmplete protease inhibitor cocktail
(Roche). After incubation for 10 min on ice, lysates were clarified by centrifugation at 20,000 xg for 20 min at 4C. Protein concen-
tration was determined according to the Bradford assay to enable normalisation between samples.
Following determination of protein concentration by Bradford assay, immunoprecipitation (IP) was utilised to isolate a particular
protein of interest. For anti-FLAG IPs, anti-FLAG M2 resin (Sigma-Aldrich) was used; for anti-ATG13 IPs, anti-ATG13 antibody
(MRC PPU Reagents & Services, S777C) was used; for anti-GFP IPs, GFP-TRAP beads (ChromoTek) were used. Before an IP
was performed, an input from each lysate was retained to compare and determine IP efficiency. Samples were incubated for 4 hr
at 4C on a rotating wheel. Beads were collected by centrifugation at 1000 xg for 1 min at 4C and a sample of the supernatant
was retained (flow-through). IPs were subsequently washed three times with lysis buffer. Input, immunoprecipitation and flow-
through samples were reduced in 2x LDS sample buffer (Invitrogen).
SDS-PAGE and Western Blotting
Cell lysates containing equal amounts of protein (10-20 mg) were resolved by SDS-PAGE and transferred to PVDF membrane. Mem-
branes were blocked in 5% (w/v) non-fat milk (Marvel) in TBS-T (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.2% Tween-20) and incu-
bated overnight at 4C in 5% (w/v) BSA/TBS-T or 5%milk/TBS-T with the appropriate primary antibodies. Primary antibodies used at
indicated dilutions include: anti-Akt (9272S, CST, 1:1,000), anti-Akt p-S473 (12694, CST, 1:1,000), anti-ATG13 (SAB4200100, Sigma-
Aldrich, 1:1,000), anti-ATG13 p-S318 (NBP2-19127, Novus, 1:1,000), anti-BRAF (702187, Thermo Fisher Scientific, 1:1,000), anti-
CK1a (A301-991A, Bethyl, 1:1,000; SA527, MRC PPU Reagents & Services, 1:1,000), anti-CUL2 (51-1800, Invitrogen, 1:1,000),
anti-EGFR (sc-03, Santa Cruz, 1:1,000), anti-EGFR p-Y1068 (3777, CST, 1:1,000), anti-ERK1/2 (9102, CST, 1:1,000), anti-ERK1/2
p-T202/Y204 (9106, CST, 1:1,000), anti-FAM83D (SA102, MRC PPU Reagents & Services, 1:1,000), anti-FIP200 (17250-1-AP, Pro-
teintech, 1:1,000), anti-FLAG (A8592, Sigma-Aldrich, 1:2,500), anti-GAPDH (2118, CST, 1:5,000), anti-GFP (S268B, MRC PPU Re-
agents & Services, 1:2,000), anti-HaloTag7 (Promega, G9281, 1:1,000), anti-HIF1a (610959, BD, 1:1,000), anti-LC3 (S400D, MRC
PPU Reagents & Services, 1:200), anti-panRAS (ab206969, Abcam, 1:500), anti-SGK3 (S848D, MRC PPU Reagents & Services,
1:1,000), anti-a-tubulin (MA1-80189, Thermo Fisher Scientific, 1:5,000), anti-mono- and poly-ubiquitinylated conjugates (BML-
PW8810, Enzo, 1:2,000), anti-ULK1 (8054, CST, 1:1,000), anti-ULK1 p-S757 (6888, CST, 1:1,000).
Membranes were subsequently washed with TBS-T and incubated with HRP-conjugated secondary antibody for 1 hr at room tem-
perature. HRP-coupled secondary antibodies used at indicated dilutions include: goat anti-rabbit-IgG (7074, CST, 1:2,500), rabbit
anti-sheep-IgG (31480, Thermo Fisher Scientific, 1:5,000), goat anti-rat IgG (62-9520, Thermo Fisher Scientific, 1:5,000), goat
anti-mouse-IgG (31430, Thermo Fisher Scientific, 1:5,000). After further washing, signal detection was performed using ECL (Merck)
andChemiDocMPSystem (Bio-Rad). ImageJ v1.49 (National Institutes of Health) was used to analyse protein bands by densitometry
(Schneider et al., 2012).
Immunofluorescence Microscopy
Cells were seeded onto sterile glass coverslips in 6-well dishes. Coverslips were washed twice with PBS, fixed with 4% (w/v) para-
formaldehyde (Thermo Fisher Scientific) for 10 min, washed twice with and incubated for 10 min in DMEM/10 mM HEPES pH 7.4.
After one wash in PBS, cell permeabilisation was carried out using 0.2% NP-40 in PBS for 4 min. Samples were blocked by washing
twice and incubation for 15 min in blocking buffer (1% (w/v) BSA/PBS). Coverslips were incubated for 1 hr at 37C with primary an-
tibodies in blocking buffer andwashed three times in blocking buffer. Mousemonoclonal anti-FLAG primary antibody (F1804, Sigma-
Aldrich) was used at a 1:500 dilution. Coverslips were then incubated for 30 min at room temperature with Alexafluor coupled sec-
ondary antibodies in blocking buffer and washed an additional three times in blocking buffer. Goat-anti-mouse IgG Alexa-Fluor 647Cell Chemical Biology 27, 1–17.e1–e5, August 20, 2020 e4
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mounted onto glass slides using ProLong gold antifade mountant with DAPI (Life Technologies) and visualised using a DeltaVision
system (Applied Precision) and deconvolved using SoftWoRx (Applied Precision). Images were processed using ImageJ and
OMERO 5.4.10 software (Allan et al., 2012). ImageJ macro quantification of mCh-CK1a spindle localisation was performed as pre-
viously described (Fulcher et al., 2019).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was determined using unpaired Student’s t-test for single comparisons and for multiple treatments analysis of
variance was performed followed by the post-hoc tests described in figure legends using Prism Version 8.0.e5 Cell Chemical Biology 27, 1–17.e1–e5, August 20, 2020
